Drug Trial Radar · NCT04346862
Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
Last checked: Nov 19, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
636
Planned (sponsor's estimate)
Start
Jan 26, 2016
Primary completion
Jun 30, 2020
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of Acetyl-L-carnitine in patient with Mild Cognitive Impairment associated with chronic cerebrovascular disease.
Conditions
- Mild Cognitive Impairment
Interventions
Acetyl-L-carnitine hydrochloride 500mgDrug
The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
PlaceboDrug
The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Interference score using K-CWST(Korean-Color Word Stroop Test)Time frame: 24 week
- Montreal Cognitive Assessment Korean(MOCA-K)Time frame: 24 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Catholic Kwandong University International St. Mary'S Hospital
Incheon, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.